In the fi eld of development of pathophysiology of pulmonary hypertension, there are growing number of signifi cant recent advances, which leads to new therapeutic agents. Traditional methods of diagnosing and monitoring this condition have comprised echocardiography and right heart catheterization, in addition to functional measures, such as estimation of functional class and the 6-min walk test. An increasing number of biomarkers have been described that are elevated in pulmonary hypertension and which may assist the clinician in diagnosis and in the assessment of disease severity and response to treatment.